FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Travere Therapeutics Plans Filspari sNDA

[ Price : $8.95]

Travere Therapeutics says it will submit an sNDA to FDA for a new indication for its Filspari to treat focal segmental glomerulosc...

Pfizer Gets Expanded Approval for Adcentris

[ Price : $8.95]

FDA approves a Pfizer supplemental BLA for Adcetris (brentuximab vedotin) in combination with lenalidomide and rituximab for treat...

Bioresearch Monitoring Issue at ISOThrive

[ Price : $8.95]

FDA warns Healdsburg, CA-based ISOThrive about failing to submit an IND for two clinical trials it sponsored of an investigational...

CGMP Deviations at Wuhu Nuowei Chemistry

[ Price : $8.95]

FDA warns Chinas Wuhu Chemistry about CGMP deviations in its manufacturing of active pharmaceutical ingredients.

Olympus Recalls Bronchoscope Guide Sheaths

[ Price : $8.95]

Olympus recalls its bronchoscope single-use guide sheath kits due to potential for the radiopaque tip of the sheath component to s...

AnaptysBio Reports Positive Data on Arthritis Drug

[ Price : $8.95]

AnaptysBio reports positive data from a Phase 2 study of rosnilimab for treating moderate-to-severe rheumatoid arthritis.

Max Mobility Recalls Wheelchair Speed Control Dial

[ Price : $8.95]

Max Mobility recalls its Max Mobility/Permobil Smart Drive MX2+ SpeedControl Dial for wheelchair use due to a faulty circuit board...

DoJ Probing Inspire Marketing, Reimbursement

[ Price : $8.95]

The Department of Justice has requested information from Inspire Medical as part of a civil probe into its marketing, promotion, a...

FDA Clarifies Compounded GLP-1 Enforcement

[ Price : $8.95]

FDA clarifies its enforcement discretion timeframes for compounded tirzepatide.

Genentech Gets New Evrysdi Tablet Approval

[ Price : $8.95]

FDA approves a Genentech NDA for a new tablet formulation of Evrysdi (risdiplam) for treating people with spinal muscular atrophy.